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Summary
Objective: To deﬁne the role of mitogen activated protein (MAP) kinases in ﬁbronectin fragment (Fn-f) mediated matrix metalloproteinase
(MMP) upregulation and damage to bovine cartilage and to compare activities of three Fn-fs with native ﬁbronectin (Fn), which is inactive
in terms of cartilage damage.
Methods: Bovine chondrocytes were cultured with three Fn-fs, an amino-terminal 29-kDa, a gelatin-binding 50-kDa and a central 140-kDa Fn-f or
native Fn at concentrations from 0.01 to 1 mM, concentrations lower than those found in osteoarthritis synovial ﬂuids. Lysates were probed for ac-
tivation ofMAP kinases, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 and stress activated protein kinase/c-jun N-terminal kinase (SAPK/
JNK). Confocal ﬂuorescentmicroscopywas used to visualizemovement of activated kinases. Kinase inhibitors were tested for their abilities to block
Fn-f mediated protein upregulation of MMP-3 and MMP-13 and Fn-f induced depletion of cartilage proteoglycan (PG) from cultured explants.
Results: The 29-kDa, the most potent Fn-f in terms of cartilage damage, enhanced phosphorylation of ERK1/2, p38 and JNK1/2 within a 1-h
incubation while the 50 and 140-kDa Fn-fs required up to 4 h for maximal activity and native Fn was only minimally active toward p38 and JNK,
but did strongly activate ERK1/2. The activated kinases displayed a distribution toward the nuclear membrane and within the nucleus. MAP
kinase inhibitors markedly decreased Fn-f mediated upregulation of MMP-3 or MMP-13 and Fn-f mediated cartilage PG depletion.
Conclusions: These results suggest that Fn-fs upregulate MMP-3 and MMP-13 in bovine chondrocytes through MAP kinases and that kinase
inhibitors afford protection against this degenerative pathway.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: Fn-f(s) ﬁbronectin fragment(s), MMP matrix metalloproteinase, PG proteoglycan, Fn ﬁbronectin, iNOS inducible NO synthetase,
MAP mitogen activated protein, ERK extracellular signal-regulated kinase, JNK N-terminal kinase, NF-kB nuclear factor kB, DMEM Dulbecco’s
modiﬁed Eagle’s medium, DAPI 40-6-Diamidino-2-phenylindole, TRITC tetramethyl rhodamine iso-thiocyanate, SDS sodium dodecyl sulfate,
DTT dithiothreitol, HRP horseradish peroxidase, SD standard deviation, DMB dimethylmethylene blue, ECM extracellular matrix, BLU Boeh-
ringer Light Unit (also integrated intensity), ERK1 44-kDa ERK, ERK2 42-kDa ERK, JNK-1 46-kDa JNK, JNK-2 54-kDa JNK, OA osteoarthritis.Introduction
We have reported that ﬁbronectin fragments (Fn-fs) have
cartilage chondrolytic activities1, elevatematrixmetalloprotei-
nase (MMP) expression2e4, suppress proteoglycan (PG)
synthesis in chondrocytes and cartilage5e7 and enhance
rates of PG loss from cartilage tissue in explant cultures1e3,5e7.
These activities involve catabolic cytokines8,9, interaction
with the ﬁbronectin (Fn) a5b1 integrin receptor
10e12 and en-
hanced release of several MMPs2e4,9. Effects of Fn-fs on cy-
tokines13 and onMMPs and aggrecan degradation have also
been conﬁrmed in porcine chondrocyte models14 as well as
effects on MMPs and on protein kinase C (PKC) and proline-
rich tyrosine kinase (PYK2) activation in human chondro-
cytes15. Our own studies of bovine chondrocytes have
shown a role for MMP-32e4 as well as aggrecanases16 which*Address correspondence and reprint requests to: Gene A.
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1253cleave within the aggrecan interglobular domain17. Several
members of the A disintegrin and metalloproteinase with
thrombospondin motifs (ADAMTS) family of proteins cleave
aggrecan at this site18e21, including ADAMTS-4 and
ADAMTS-518,19 which are increased by inﬂammatory cyto-
kines and which when overexpressed enhance cartilagema-
trix degradation22e26. Both forms are expressed in normal
and osteoarthritis (OA) cartilage and synoviium24 and their
inhibition correlates with prevention of aggrecan degradation
in vitro24,27. Thus, the ability of Fn-fs to induce aggrecanase
like cleavage supports their potential relevance. Since the
Fn-fs also upregulate inducible NO synthetase (iNOS)28 as
well as the Toll-like receptor 229, the Fn-fs have diversiﬁed
effects in inﬂammatory pathways.
The potential consequences of the Fn-fs on cartilage
tissue pathology in vivo are severe since PG depletion
from mature cartilage explants caused by the Fn-fs in vitro
appears to be irreversible6,7. The relevance of the Fn-f
model is supported by our observations that injection of
Fn-fs into normal rabbit knee joints causes a severe loss
of articular cartilage PG30,31. Biochemical aspects of this
model have been reviewed32.
The physiologic relevance of Fn-fs to cartilage degenera-
tion has been investigated in several ways.Wehave detected
1254 L. Ding et al.: Fibronectin fragments activate MAP kinasesseveral 30e200-kDa Fn-fs in human OA cartilage using
a monoclonal antibody speciﬁc for the N-terminus and
demonstrated that IL-1 activates bovine cartilage to generate
30e200-kDa Fn-fs and that removal of Fn-fs from OA
synovial ﬂuids reduces the cartilage damaging activity of
OA synovial ﬂuids33. We also showed that fragmentation of
Fn forms isolated from bovine synovial ﬂuid, bovine cartilage
or bovine plasma generates Fn-fs with similar cartilage dam-
aging activities33. Others have recently shown that 30-kDa
gelatin-binding Fn-fs isolated from OA cartilage enhance
aggrecanase like cleavage of aggrecan in bovine cartilage34.
Thus, it is highly likely that a broad range of cartilage damag-
ing Fn-fs can be found in OA cartilage and synovial ﬂuids.
Little is known of how the Fn-fs alter signal transduction
pathways. Fn-fs might compete with native Fn and cause dis-
sociation of thematrix fromdirect or indirect interactionwith the
Fn receptor. Detachment of Fn from matrix interaction has
been shown in other cell types to alter signaling, including de-
creasing cellular proliferation35, stimulating cyclin dependent
kinases and DNA synthesis and activating mitogen activated
protein (MAP) kinases36. Since detachment has been shown
to enhance integrin internalization and degradation37, Fn-fs
might cause such detachment and alter or even abolish nor-
mal integrin signaling. In fact, it has been shown that Fn-fs
can activate MAP kinases as correlated with NO production38
and as correlated with MMP-13 production39 as well as
activate nuclear factor kB (NF-kB) as correlated with cytokine
production40 and MMP-13 upregulation41. However, there
have not been any studies that correlate MAP kinase activa-
tion with Fn-f mediated cartilage damage.
We have compared MAP kinase activation properties of
three different Fn-fs, with different MMP upregulation and
cartilage damaging activities and differing abilities to bind
Fn receptors and cartilage matrix, to determine how kinase
activation correlates with cartilage damage. Comparisons
have also been made to native Fn which has limited
cartilage damaging activity and may actually serve as an
inhibitor of the Fn-f pathway32.
Experimental proceduresISOLATION OF Fn AND Fn-fsFn was isolated from human plasma and a well-
characterized amino-terminal heparin-binding 29-kDa Fn-f,
a gelatin-binding 50-kDa Fn-f and 70e140-kDa Fn-fs as
well as smaller C-terminal Fn-fs isolated as described1 as
well as an MMP-3 digest, denoted MMP-3D42. We have
identiﬁed the 29-kDa Fn-f in this mixture27 and shown that
this mixture has potent cartilage damaging activity42,43.EXPLANT CARTILAGE CULTURES AND CHONDROCYTES’
CULTURESExplant cartilage cultures and chondrocytes’ cultures
were prepared as described elsewhere11,12. At the end of
the experiments, cultures were tested for cell viability using
the LIVE/DEAD Reduced Biohazard Viability/Cytotoxicity
Kit #1 (L-7013) as directed by the manufacturer.LABELING AND VISUALIZATION OF Fn-fs AND KINASES
BY CONFOCAL FLUORESCENT MICROSCOPYProtein was conjugated to rhodamine and added to
chondrocytes plated in 10% serum/Dulbecco’s modiﬁed
Eagle’s medium (DMEM) into eight well chamber slides
with 0.15 million cells per well. Four hours after addition ofrhodamine-labeled Fn-fs, cells were rinsed, ﬁxed and
visualized on a Zeiss 510 META confocal microscope
equipped with a spectral META detector.
To visualize movement of kinases toward nuclear
membrane, cells in chamber slides, after being blocked by 5%
donkey serum diluted in 0.5% bovine serum albumin (BSA)e
phosphate buffered saline (PBS), were probed with antibodies
to kinases, followed by reaction with rhodamine [tetramethyl
rhodamine iso-thiocyanate (TRITC)] conjugated AfﬁniPure
donkey anti-rabbit IgG. Cell nuclei were stained with 300 nM
40-6-diamidino-2-phenylindole (DAPI) dihydrochloride.WESTERN BLOTTING AND CHEMILUMINESCENT DETECTIONFor kinase detection, lysates were subjected to electro-
phoresis on 10% acrylamide gels, the gels blotted and blots
were blocked for 1 h with 5% nonfat dry milk in 20 mM Tris
buffer, pH 7.4, containing 140 mM NaCl [tris buffered saline
(TBS)] and 0.1% TBS-Tween 20 (TBST). The blots were
then incubated with the anti-total or anti-phosphospeciﬁc ki-
nase antibodies in a 1:1000 dilution in 5% BSA in TBST
(BSA/TBST) overnight and after washing, the blots were re-
acted with horseradish peroxidase (HRP) conjugated goat
anti-rabbit immunoglobulin G (IgG) in a 1:2000 dilution in
5% BSA/TBST for 1 h, followed by addition of Supersignal
West Dural Extended Duration substrate. Densities of
bands were measured by a LumiImager with Boehringer-
eMannheim LumiAnalyst 3.0 software. For MMP detec-
tion, the blots were blocked with 3% BSA in TBS
overnight and incubated with anti-MMP-3 or MMP-13 anti-
body in 1:5000 or 1:3000 dilution, respectively. The blots
were then incubated with peroxidase conjugated goat
anti-rabbit IgG from Sigma 1:12,000 diluted in 1% BSA/
TBST for 1 h. Subsequently blots were incubated with sub-
strate and visualized as described above.KINASE ACTIVATION STUDIESFor kinetic studies, cellswere treatedwith 0.5 mMFnor Fn-fs
for various times and lysed in cold lysis buffer: 150 mM NaCl,
10 mM Tris, pH 7.5, 0.1% sodium dodecyl sulfate (SDS), 1%
Triton X-100, 1% sodium deoxycholate, 1 mM ethylene glycol
tetraacetic acid (EGTA), 50 mM NaF, 1 mM Na3VO4, 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 10 mg/ml aprotinin,
10 mg/ml leupeptinwitha1:500 folddilutionofprotease inhibitor
cocktail II. Lysates were centrifuged at 2000 g for 10 min at
4C and supernatants recovered for analysis. For dosee
response effects, cultures were adjusted to 10 nM to 1 mM Fn
or Fn-fs and cell lysates were recovered at 1 or 4 h.TESTS OF KINASE INHIBITORS ON MMP
UPREGULATION BY THE 29-kDa Fn-fThe inhibitors tested were PD98059 for extracellular
signal-regulated kinase 1/2 (ERK1/2); SB202190 and
SB203580 for p38 and SP600125 for N-terminal kinase
(JNK). Inhibitors were added over a 100 fold concentra-
tion range that included effective concentrations reported
by others: 100 mM for PD9805928,29, 20 mM for SB2
0219029e31, 30 mM for SB203580 and 20 mM for SP600
12530,32. Inhibitors were typically dissolved in dimethyl-
sulfoxide (DMSO) to a ﬁnal concentration in culture of
0.4% and inhibitors were added 2 h prior to addition of
0.5 mM 29-kDa Fn-f. After 24 h, media were collected, di-
alyzed against water, concentrated 10, denatured with
sample buffer and reduced with 0.05 M dithiothreitol
(DTT) for electrophoresis and blotting.
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MEDIATED CARTILAGE DAMAGE, AS DEFINED BY DECREASES
IN CARTILAGE PG CONTENTBovine cartilage explants in 10%serum/DMEMwere prein-
cubated with inhibitors for 24 h and then adjusted to 0.5 mMof
the MMP-3 digest of Fn (MMP-3D). Media and reagents were
renewed every other day. After 7 days in 10% serum/DMEM,
cartilage was recovered, weighed, subjected to papain
digestion andPGcontent wasmeasuredwith dimethylmethy-
lene blue (DMB) reagent as described2. The ﬁnal mean and
standard deviation (SD) values of PG content were compared
using two-tailed unpaired Student’s t tests.MATERIALSTotal and phosphospeciﬁc ERK1/2 (Thr202/Tyr204), JNK
(Thr183/Tyr185), p38 (Thr180/Tyr182) antibodies and HRP-
conjugated goat anti-rabbit IgG were purchased from Cell
Signaling Technology (Danvers, MA). NHS-rhodamine
[5-(and 6)-carboxylﬂuorescein, succinimidyl ester], the
Super Signal Chemiluminescent Substrate kit for HRPFig. 1. Location of Fn-f domains, homogeneity of Fn-fs and demonstration
intact polypeptide is shown in Fig. 1A as well as their potential interaction
Fn-fs generated by MMP-3 digestion were generated from human plasm
different 10% acrylamide gels with separator lanes and gels stained with
to construct the montage. Lanes are the Fn solution used to generated
(50), the isolated 29-kDa Fn-f (29) and the MMP-3 digest (MMP-3D). Pa
followed by ﬂuorescent coand the Modiﬁed Lowry Protein Assay Kit were from Pierce
Chemical Co. (Rockford, IL). Polyclonal antibodies to
human MMP-3 and MMP-13 were from Chemicon Interna-
tional Inc. (Temecula, CA). DMEM and the secondary
antibody used for MMP detection were purchased from
SigmaeAldrich (St. Louis, MO). The kinase inhibitors and
protease inhibitor cocktail II were from CalBiochem (San
Diego, CA). Rhodamine (TRITC)-conjugated AfﬁniPure
donkey anti-rabbit IgG (Hþ L) was purchased from Jackson
ImmunoResearch Laboratories, Inc. (West Grove, PA).
DAPI dihydrochloride (FluoroPure grade) and the LIVE/
DEAD Reduced biohazard Viability/Cytotoxicity Kit #1
(L-7013) were purchased from Invitrogen (Carlsbad, CA).ResultsTESTING OF HIGHLY HOMOGENEOUS Fn-fsThe location within native Fn of the Fn-fs studied here is
shown in Fig. 1(A) as well as potential interactions of Fn-fs
with PG and collagen in the extracellular matrix (ECM). Theof chondrocyte interaction. Panel A: the location of these Fn-fs in the
s with PG and collagen in the ECM. Panel B: Fn-fs and a mixture of
a Fn. Fn and Fn-fs were subjected to SDS electrophoresis on two
Coomassie R-250. The empty lanes were cut and lanes merged
Fn-fs (Fn lane), the 140-kDa Fn-f (140), the isolated 50-kDa Fn-f
nel C: Fn-fs were rhodamine labeled and added to chondrocytes,
nfocal microscopy.
1256 L. Ding et al.: Fibronectin fragments activate MAP kinasesthree Fn-fs differ in potencies in terms of causing cartilage
damage and differ in interactions with the a5b1 Fn receptor.
Figure 1(B) shows the results of SDS gel electrophoresis
on 10% acrylamide gels of reduced samples of proteins
used for these studies. As shown, the sample of reduced
Fn has subunits of approximately 250 kDa and is relatively
devoid of Fn-fs while the 140-kDa Fn-f has some contaminat-
ing lower mass material and the 50-kDa Fn-f has additional
higher massmaterial. The 29-kDa Fn-f contains some higher
mass bands but is highly enriched. TheMMP-3Dmixturewas
generated by addition of MMP-3 to native Fn and has been
partially characterized by us42,43. The MMP-3D lane shows
an approximately 30-kDa Fn-f which is identical to the throm-
bin-generated 29-kDa Fn-f studied here as shown using
mass spectrometry/sequence analysis43.
Figure 1(C) demonstrates that rhodamine-labeled native
Fn and Fn-fs have afﬁnity to isolated chondrocytes and
thus have the potential to affect cell signaling. Note that
the Fn-fs appear to bind in different patterns and all bind
to a greater extent than BSA used as a negative control.
The 29-kDa Fn-f bound in more diffuse patterns, while the
140-kDa Fn-f bound in a more concentrated punctate pat-
tern. Both show less diffuse cytosolic distribution than theFig. 2. Effect of Fn-fs and Fn on kinetics of activation of ERK1/2 and dose d
0.5 mM of each Fn-f or Fn and lysed at 0, 0.25, 1.0, 4.0 and 12.0 h; or (B) c
0.01 to 1.0 mM and cell lysates were recovered at 1 h; or (C) cells were trea
but cell lysates were recovered at 4 h. Proteins were ﬁrst reduced with 0.5
trophoresis (PAGE) and the blots probed with anti-total (t-) or phospho (p)
minescent substrate was used to visualize ERK1/2 bands on a nitrocellulos
lysates from MMP-3 digest treated cells such that the two activities could b
responds to 0.5 mM 29-kDa Fn-f treated lysate so the activities of the other50-kDa Fn-f. Native Fn shows some diffuse binding but
also bound mainly on the cell membrane. Thus, the three
Fn-fs appear to differ in their interaction targets.ALL THREE Fn-fs AND Fn KINETICALLY AND
DOSE-DEPENDENTLY ENHANCED PHOSPHORYLATION OF
ERK1/2 KINASESAs preliminary baseline data we found there was no
enhanced phosphorylation of p38 or JNK with time in
untreated chondrocytes, while basal phosphorylation of
ERK1/2 activation appeared to decrease by 4 h (data not
shown). In other experiments, 0.5 mM BSA as a negative
protein control did not enhance activation (data not shown).
Our preliminary data showed maximal effects of Fn-fs on
MAP kinases between 0.3 and 1 mM so a midpoint concen-
tration of 0.5 mM was used for the kinetic studies.
As shown in Fig. 2(A), all three Fn-fs and Fn at 0.5 mM
enhanced phosphorylation of 44-kDa ERK (ERK1) and
42-kDa ERK (ERK2). The effects were maximal within
15 min and elevated for at least 4 h with effects of the
140-kDa Fn-f and Fn decreasing by 12 h. Figure 2(B) shows
that all three Fn-fs had a concentration dependency withependency. After 22 h of serum starvation, (A) cells were treated with
ells were treated with the Fn-fs or Fn at concentrations ranging from
ted with the same concentration range of the 50-kDa or 140-kDa Fn-f,
M DTT and then resolved on a 10% SDS-polyacrylamide gel elec-
ERK1/2 antibody. HRP linked goat anti-rabbit antibody and chemilu-
e membrane. In (B), in the 29-kDa strip, the M/N lane corresponds to
e compared and in the 50-kDa, 140-kDa and Fn strips, the M/N cor-
proteins could be compared to the most potent Fn-f, the 29-kDa Fn-f.
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creases in 50-kDa Fn-f samples were less than for the other
Fn-fs. The far right lane of the gel of the 29-kDa Fn-f
samples corresponds to a 1-h 0.5 mM MMP-3D treatment
(0.5 M/N) and shows activity similar to the 0.3e1 mM
29-kDa Fn-f. The far right lanes in gels of the 50-kDa,
140-kDa Fn-f and Fn samples (0.5 M/N) correspond to
a 1-h 0.5 mM 29-kDa Fn-f incubation as a positive control.
The effects of Fn were evident at 0.01 mM, while 1 mM
appeared to decrease phosphorylation. The effects of
0.5 mM 29-kDa Fn-f at 1 h were quantiﬁed as increases in
intensity for the ERK2 bands as compared with controls.
With three experiments the effects of ERK2 were 9.8 4
(S.E.M.) fold. As shown in Fig. 2(C), the dose dependent
effects of the 50 and 140-kDa Fn-fs still occurred at 4 h.
BSA negative controls (not shown) had no detectable
effects. Similar data were obtained with three different
chondrocyte preparations.THE THREE Fn-fs HAD DIFFERENTIAL EFFECTS ON
46-kDa JNK (JNK-1) AND 54-kDa JNK (JNK-2)As shown in Fig. 3(A), all three Fn-fs at 0.5 mM enhanced
phosphorylation of 46-kDa JNK-1 by 15 min, while native
Fn had far weaker effects. This Fn-f burst subsequently
decreased to baseline by 12 h. The 29-kDa Fn-f also
increased activation of JNK-2 (p54) at 1 h while the 50-kDa
or 140-kDa Fn-fs only had weak effects. Probing for b-actinFig. 3. Effect of Fn-fs and Fn on kinetics of activation of JNK1/2 and dos
kinetic data, panel B represents doseeresponse data at 1 hasa secondary loading control conﬁrmedeven loadingof pro-
tein for not only the JNK blots but other kinase blots as well.
Figure 3(B) showsdoseeresponse data for a 1-h incubation
and shows that the 29-kDa Fn-f was effective from 0.1 to
1.0 mM in mostly enhancing the JNK-1 isoform although
weak effects on JNK-2 were detectable. The 50 kDa at
1 mM enhanced JNK-1 while the effects of the 140-kDa and
Fn were far weaker. Neither the 50 or 140-kDa Fn-fs, nor
Fn, had detectable effects on JNK-2 at 1 h. The far right
lane in the gel for 29-kDa Fn-f treatment in panel B for a 1-h
0.5 mM MMP-3D incubation suggests similar activities for
both treatments while the far right lanes in gels for 50 or
140-kDaFn-f samples for a 1-h 0.5 mM29-kDaFn-f incubation
show the much greater activity of the 29-kDa Fn-f. The effects
of 1 mM 29-kDa Fn-f at 1 h were a 9.7 2.6 fold increase for
JNK-1 as compared with untreated control at 1 h. The effects
of 0.5 mM 29-kDa Fn-f were compared with those of a 1-h
incubation with human interleukin-1b (hIL-1b) from 0.02 to
5 ng/ml. Dosedependent effects of the cytokinewere observed
and effects at 5 ng/ml were similar in intensity and JNK iso-
form distribution to that of the 29-kDa Fn-f (data not shown).
Panel C shows that at 4 h, 1 mM 50 and 140-kDa Fn-f
increased phosphorylation of not only JNK-1, but also JNK-2.THE THREE Fn-fs ENHANCED p38 MAP KINASE ACTIVATIONAs shown in Fig. 4(A), the three Fn-fs enhanced p38
phosphorylation by 15 min which was prolonged throughe dependency e conditions were as in Fig. 2. Panel A represents
and panel C represents doseeresponse data at 4 h.
Fig. 4. Effect of Fn-fs and Fn on kinetics of activation of p38 and dose dependency e conditions as in Fig. 2.
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ducible decrease was observed at 1 h, as also observed for
the JNK1/2 blots. Native Fn did not show enhanced p38
activation even with a 12-h incubation.
Figure 4(B) shows that with a 1-h incubation, the 29-kDa
Fn-f was effective from 0.01 to 1 mM. The MMP-3D Fn-f
mixture showed effects similar to those of the 29-kDa
Fn-f. However, the 50 and 140-kDa Fn-fs had very weak
effects as compared to the 29-kDa Fn-f treatment, shown
in the far right lanes. Fn was ineffective over the same
concentration range as compared with the 29-kDa Fn-f
positive control in the far right lane. The fold increases as
compared with controls for the 1 mM 29-kDa Fn-f at 1 h
were 11.6 3.3. The intensity of the signal for 0.5 mM
29-kDa Fn-f was similar to that of 5 ng/ml hIL-1b (data not
shown). With a 4-h incubation [Fig. 4(C)], the 50 and
140-kDa Fn-fs did show dose dependent effects and were
active at concentrations as low as 0.1 mM.IN THE PRESENCE OF Fn-fs, PHOSPHORYLATED MAP
KINASES HAD A NUCLEAR AND PLASMA MEMBRANE
DISTRIBUTIONCells were treated with the 29-kDa Fn-f for 4 h, ﬁxed and
then reacted with the nuclear staining dye DAPI as well as
antibodies to phosphorylated kinases. Figure 5 shows in
untreated cells a clear nuclear blue pattern with little stain-
ing with TRITC labeled anti-phospho-kinases. In contrast,
treatment with the 29-kDa Fn-f for 4 h markedly enhanced
colocalization of phospho-ERK, p38 or JNK with the nuclear
membrane and within the nucleus. Note the red tint in the
otherwise blue nucleus and the formation of red bodieswithin the nucleus. Some red staining of the cell membrane
of Fn-f treated cells is also obvious with all three antibodies.
The far two columns show some of the cells enlarged (enl)
by a few fold and the images further illustrate the marked
effects of the Fn-fs. Fn treated cells showed patterns
more similar to untreated cells for p38, JNK1/2 and ERK1/
2 (data not shown).THREE Fn-fs UPREGULATED MMP-3 AND MMP-13 AT
DIFFERENT RATES BUT Fn DID NOT ENHANCE MMP
EXPRESSION AND MAP KINASE INHIBITORS DECREASED
29-kDa Fn-f MEDIATED UPREGULATION OF MMPsTo provide baseline data for testing effects of MAP
kinase inhibitors, chondrocyte cultures were treated with
Fn-fs or Fn and at various times media were probed for
MMPs. Figure 6 (top) shows that neither MMP-3 nor
MMP-13 was upregulated over a 48-h period in untreated
controls as compared with a 24-h 0.5 mM 29-kDa Fn-f treat-
ment (far right lane, *24). However, treatment with the
29-kDa Fn-f upregulated MMP-3 by 8 h and MMP-13 by
24 h. The major MMP-3 and MMP-13 bands corresponded
to their zymogen forms at 59 and 60-kDa, respectively.
The 50 and 140-kDa Fn-fs had similar effects and
enhanced both MMPs by 24 h. Native Fn had no detect-
able effects on MMP-3 and MMP-13. The far right lane in
the Fn gel corresponds to a 24-h incubation of 0.5 mM
29-kDa Fn-f as a positive control. Because of the signiﬁ-
cant effect by 24 h for all three Fn-fs, this time point was
used for further studies.
Cultures were next adjusted to various concentrations of
kinase inhibitors and expression of MMP-3 and MMP-13
Fig. 5. Effect of Fn-f on intracellular distribution of phosphorylated MAP kinases. Cells were incubated in DMEM with 10% serum for 4e5 days
in eight well chamber slides and then serum deprived for 22 h. The 29-kDa Fn-f was added and after 4 h cells were ﬁxed and analyzed for
distribution of p-ERK1/2, p-p38 and p-JNK by ﬂuorescent confocal microscopy. Cells were counterstained with DAPI to visualize the nucleus.
Control cells were untreated. Cont Enl and 29-kDa Enl were arbitrarily chosen ﬁelds that were enlarged to enhance visualization.
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in Fig. 7, the DMSO carrier had no effect on MMP
expression and the inhibitors by themselves at the highest
concentrations tested had no effect on MMP expression.
However, the MAP kinase inhibitors decreased the effects
of the 29-kDa Fn-f on both MMPs.MAP KINASE INHIBITORS ALSO BLOCKED Fn-f
MEDIATED CARTILAGE DAMAGETo conﬁrm an active role for the MAP kinases in Fn-f
mediated damage to cartilage, explants were cultured in
the presence of MAP kinase inhibitors for 24 h prior to the
MMP-3D. As shown in Fig. 8, addition of Fn-f in 0.4%
DMSO in media (Dþ f) or Fn-f in media (f) decreased PG
content to a signiﬁcant extent by 7 days as compared to
cartilage only treated with 0.4% DMSO in media (D). The in-
hibitors by themselves in DMSO (PD, SP and SB) did not
signiﬁcantly decrease PG content. However, the ERK1/2
inhibitor (PD98059) in the presence of Fn-f increased PG
content to above DMSO treated levels (D). The JNK1/2
inhibitor (SP600125) and the p38 inhibitor (SB202190)
decreased the PG depletion activity of the Fn-f.Discussion
Our objectives were to characterize the role of MAP kinases
in Fn-f mediated MMP upregulation and cartilage by
comparing three different Fn-fs with different cartilage dam-
age potentials and with different afﬁnities for cartilage tis-
sues and for the isolated a5b1 integrin. The 29-kDa Fn-f is
the most potent damaging Fn-f, followed by the 50-kDa
Fn-f and ﬁnally the 140-kDa Fn-f1. The 29-kDa Fn-f has
afﬁnity to heparin1,44, the 50-kDa Fn-f can bind tightly to
gelatin and collagen1, and the 140-kDa Fn-f binds weakly
to heparin44 and to the protein core of heparin sulfate
PG45. Since only the 140-kDa Fn-f has cell binding activi-
ties, yet all three alter intracellular signaling and upregulate
MMPs, it is likely that Fn-f interaction with the matrix itself
indirectly activates integrins.
The concentration range studied here, up to mM, was
within the range we have reported for 30e200-kDa Fn-fs
detected in OA synovial ﬂuids46 and for similar sized Fn-fs
found in OA cartilage extracts as detected with an amino-
terminal speciﬁc antibody33. The amino-terminal 29-kDa
Fn-f studied here might be very relevant to the chondrolytic
state in OA, since a 30-kDa amino-terminal Fn-f can be
Fig. 6. Effect of Fn-fs and Fn on kinetics of upregulation of MMP-3
and MMP-13. Cells were incubated in DMEM with 10% serum for
4e5 days until cells reached 70e80% conﬂuency and then serum
deprived for 22 h. Media were changed to fresh DMEM 2 h prior
to the addition of Fn-fs or Fn. Media were recovered at 0, 1, 3, 8,
24 and 48 h. After dialysis against water, media were concentrated
to 10, denatured with 2 sample buffer and then reduced with
0.05 M DTT. Equal amounts of sample were reduced with 0.5 M
DTT and loaded onto a 10% SDS-PAGE gel. After electrophoresis,
proteins were transferred onto a nitrocellulose membrane and
probed with anti-MMP-3 or MMP-13 antibody. Sample treated by
the 29-kDa Fn-f for 24 h was loaded onto the last lane of Fn as
a positive control. The nontreated controls’ panels show the
59-kDa positions of MMP-3 and MMP-13.
Fig. 7. Effect of MAP kinase inhibitors on Fn-f mediated MMP-3 and MMP-
some cultures were preincubated with a series of concentration of inhibito
treated with or without 0.5 mM 29-kDa Fn-f for 24 h. Lanes shown are fo
addition of inhibitor in DMSO for 2 h, followed by addition of Fn-f and a
as in Fig. 6. The top strips show the positi
1260 L. Ding et al.: Fibronectin fragments activate MAP kinasesdetected in OA cartilage extracts by amino-terminal speciﬁc
antibodies33.
All three Fn-fs bound to chondrocytes consistent with their
abilities to alter cellular signaling. The three Fn-fs and Fn
enhanced activation of ERK1/2 within 15 min with sustained
effects up to 12 h. Fn appeared to have similar effects but
was active at concentrations lower than the Fn-fs. The obser-
vation that Fn-fs enhanced ERK activation is interesting
since ERK is involved in growth factor pathways, although
recent observations also suggest catabolic roles47e51.
The three Fn-fs activated JNK-1 within 15 min to varying
degrees and with subsequent declining effects. In contrast,
the Fn-fs had more prolonged effects on p38. The 29-kDa
Fn-f appeared to have the greatest effects on both kinases
and at lower concentrations. The 29-kDa Fn-f had maximal
effects within 1 h, while the 50 and 140-kDa Fn-f required
higher concentrations and up to 4 h for maximal effects, es-
pecially for JNK isoforms. Native Fn was minimally active
toward p38 and JNK consistent with the observation that
Fn does not upregulate MMPs nor enhance cartilage
damage1. The activation of the MAP kinases by Fn-fs was
conﬁrmed by observation of phosphorylated kinases on
the nuclear membrane a known property of activated
MAP kinases54e56.
The observation that JNK-2 was enhanced by the 29-kDa
Fn-f within 1 h but only weakly by the other two Fn-fs at 4 h
was especially interesting since JNK isoforms have been
reported to vary in terms of their interaction with activating
transcription factor 2 (ATF2), Elk-1 and Jun transcription
factors52 and JNK plays a key role in MMP expression
and joint destruction in inﬂammatory arthritis53.
The longer time required for maximal effects of the 50 and
140-kDaFn-fs and the enhancement of p38 activity up to 12 h
bring into question the role of secondary pathways that might
explain some of these observations. For example, cytokine
pathways might contribute to Fn-f mediated MAP kinase ac-
tivation. We have shown that Fn-fs enhance levels of tissue
necrosis factor-a (TNF-a) and interleukin-1b (IL-1b) protein13 upregulation. Cells were cultured and treated as in Fig. 6, except
rs, SB203580, SB202190, SP600125 or PD98059 for 2 h and then
r DMSO alone (0.4% DMSO), addition of Fn-f with DMSO (Fn-f) or
nalysis after 24 h (lanes with þ sign). Then media were analyzed
ons of 59-kDa MMP-3 and MMP-13.
Fig. 8. Effect of MAP kinase inhibitors on Fn-f mediated cartilage
matrix PG depletion in 10% serum 7 day cultures. Bovine cartilage
in 10% serum/DMEM and 0.4% DMSO was cultured with inhibitors
to MAP kinases for 24 h before Fn-f treatment and after 7 days, car-
tilage was recovered, weighed, subjected to papain digestion and
PG content measured with DMB reagent. D represents cartilage
treated with 0.4% DMSO, Dþ f is cartilage treated with DMSO
and Fn-f, f is Fn-f alone, PD is PD98059 for inhibition of MAP kinase
kinase 1/2 (MEK 1/2), SP is SP600125 for inhibition of JNK and
SB202190 (SB) is for inhibition of p38. Bars are SD values.
**P< 0.01 and ***P< 0.005 as compared to control untreated.
1261Osteoarthritis and Cartilage Vol. 16, No. 10and that they play active roles in Fn-fmediated cartilage dam-
age8,9. Early kinase activation might lead to cytokine upregu-
lation and downstream participation of a cytokine/MAP
kinase driven catabolic pathway.
MMP-3 was a focus because we have shown it to be
a major player in Fn-f mediated cartilage damage3 and
MMP-13 was of particular interest since it mimics, in a trans-
genic mouse model, joint changes characteristic of OA57,58.
All three Fn-fs upregulated both MMPs by 8 h. As with
differences in kinetics of activation of MAP kinases, the
strongest cartilage damaging Fn-f, the 29-kDa Fn-f, upregu-
lated MMPs faster than the other two Fn-fs. Tests of MAP
kinase inhibitors showed an active role for the MAP kinases
and that MMP-3 and MMP-13 production could be
decreased in a parallel fashion. While our data suggest
parallel effects, a single MAP kinase inhibitor does not
always affect these two MMPs in parallel47,50,59,60.
A recent report has shown that the p38 inhibitor,
SB202190, above 5 mM also inhibits JNK61. Thus, our
inhibition of p38 at 2 mM might have been partly due to
a small effect on JNK, however SB203580, another p38
kinase inhibitor, also inhibited Fn-f activity and this inhibitor
has been reported by the manufacturer to be speciﬁc at
100 mM, 10 times the concentration studied here. Further,
the JNK inhibitor we used, SP600125, only has nonspeciﬁc
effects toward p38 at 25 mM62 and our studies were at 2 mM.
However, it is still possible that these kinase inhibitors did
inhibit the alternate kinase to a small extent. These inhibi-
tors also decreased cartilage damage by Fn-fs, a signiﬁcant
observation, since there are few studies showing efﬁcacy of
kinase inhibitors in decreasing cartilage damage although
there is much interest in targeting OA with kinase
inhibitors63.Conﬂict of interest
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